Enhanced Predictive Capability of a 1-Hour Oral Glucose Tolerance Test: A Prospective Population-Based Cohort Study

To examine whether the 1-h blood glucose measurement would be a more suitable screening tool for assessing the risk of diabetes and its complications than the 2-h measurement. We conducted a prospective population-based cohort study of 4,867 men, randomly selected from prespecified birth cohorts bet...

Full description

Saved in:
Bibliographic Details
Published inDiabetes care Vol. 41; no. 1; pp. 171 - 177
Main Authors Pareek, Manan, Bhatt, Deepak L., Nielsen, Mette L., Jagannathan, Ram, Eriksson, Karl-Fredrik, Nilsson, Peter M., Bergman, Michael, Olsen, Michael H.
Format Journal Article
LanguageEnglish
Published United States American Diabetes Association 01.01.2018
Subjects
Online AccessGet full text

Cover

Loading…
Abstract To examine whether the 1-h blood glucose measurement would be a more suitable screening tool for assessing the risk of diabetes and its complications than the 2-h measurement. We conducted a prospective population-based cohort study of 4,867 men, randomly selected from prespecified birth cohorts between 1921 and 1949, who underwent an oral glucose tolerance test with blood glucose measurements at 0, 1, and 2 h. Subjects were followed for up to 39 years, with registry-based recording of events. Discriminative abilities of elevated 1-h (≥8.6 mmol/L) versus 2-h (≥7.8 mmol/L) glucose for predicting incident type 2 diabetes, vascular complications, and mortality were compared using Kaplan-Meier analysis, Cox proportional hazards regression, and net reclassification improvement. Median age was 48 years (interquartile range [IQR] 48-49). During follow-up (median 33 years [IQR 24-37]), 636 (13%) developed type 2 diabetes. Elevated 1-h glucose was associated with incident diabetes (hazard ratio 3.40 [95% CI 2.90-3.98], < 0.001) and provided better risk assessment than impaired glucose tolerance (Harrell concordance index 0.637 vs. 0.511, < 0.001). Addition of a 1-h measurement in subjects stratified by fasting glucose provided greater net reclassification improvement than the addition of a 2-h measurement (0.214 vs. 0.016, respectively). Finally, the 1-h glucose was significantly associated with vascular complications and mortality. The 1-h blood glucose level is a stronger predictor of future type 2 diabetes than the 2-h level and is associated with diabetes complications and mortality.
AbstractList To examine whether the 1-h blood glucose measurement would be a more suitable screening tool for assessing the risk of diabetes and its complications than the 2-h measurement.OBJECTIVETo examine whether the 1-h blood glucose measurement would be a more suitable screening tool for assessing the risk of diabetes and its complications than the 2-h measurement.We conducted a prospective population-based cohort study of 4,867 men, randomly selected from prespecified birth cohorts between 1921 and 1949, who underwent an oral glucose tolerance test with blood glucose measurements at 0, 1, and 2 h. Subjects were followed for up to 39 years, with registry-based recording of events. Discriminative abilities of elevated 1-h (≥8.6 mmol/L) versus 2-h (≥7.8 mmol/L) glucose for predicting incident type 2 diabetes, vascular complications, and mortality were compared using Kaplan-Meier analysis, Cox proportional hazards regression, and net reclassification improvement.RESEARCH DESIGN AND METHODSWe conducted a prospective population-based cohort study of 4,867 men, randomly selected from prespecified birth cohorts between 1921 and 1949, who underwent an oral glucose tolerance test with blood glucose measurements at 0, 1, and 2 h. Subjects were followed for up to 39 years, with registry-based recording of events. Discriminative abilities of elevated 1-h (≥8.6 mmol/L) versus 2-h (≥7.8 mmol/L) glucose for predicting incident type 2 diabetes, vascular complications, and mortality were compared using Kaplan-Meier analysis, Cox proportional hazards regression, and net reclassification improvement.Median age was 48 years (interquartile range [IQR] 48-49). During follow-up (median 33 years [IQR 24-37]), 636 (13%) developed type 2 diabetes. Elevated 1-h glucose was associated with incident diabetes (hazard ratio 3.40 [95% CI 2.90-3.98], P < 0.001) and provided better risk assessment than impaired glucose tolerance (Harrell concordance index 0.637 vs. 0.511, P < 0.001). Addition of a 1-h measurement in subjects stratified by fasting glucose provided greater net reclassification improvement than the addition of a 2-h measurement (0.214 vs. 0.016, respectively). Finally, the 1-h glucose was significantly associated with vascular complications and mortality.RESULTSMedian age was 48 years (interquartile range [IQR] 48-49). During follow-up (median 33 years [IQR 24-37]), 636 (13%) developed type 2 diabetes. Elevated 1-h glucose was associated with incident diabetes (hazard ratio 3.40 [95% CI 2.90-3.98], P < 0.001) and provided better risk assessment than impaired glucose tolerance (Harrell concordance index 0.637 vs. 0.511, P < 0.001). Addition of a 1-h measurement in subjects stratified by fasting glucose provided greater net reclassification improvement than the addition of a 2-h measurement (0.214 vs. 0.016, respectively). Finally, the 1-h glucose was significantly associated with vascular complications and mortality.The 1-h blood glucose level is a stronger predictor of future type 2 diabetes than the 2-h level and is associated with diabetes complications and mortality.CONCLUSIONSThe 1-h blood glucose level is a stronger predictor of future type 2 diabetes than the 2-h level and is associated with diabetes complications and mortality.
To examine whether the 1-h blood glucose measurement would be a more suitable screening tool for assessing the risk of diabetes and its complications than the 2-h measurement. We conducted a prospective population-based cohort study of 4,867 men, randomly selected from prespecified birth cohorts between 1921 and 1949, who underwent an oral glucose tolerance test with blood glucose measurements at 0, 1, and 2 h. Subjects were followed for up to 39 years, with registry-based recording of events. Discriminative abilities of elevated 1-h (≥8.6 mmol/L) versus 2-h (≥7.8 mmol/L) glucose for predicting incident type 2 diabetes, vascular complications, and mortality were compared using Kaplan-Meier analysis, Cox proportional hazards regression, and net reclassification improvement. Median age was 48 years (interquartile range [IQR] 48-49). During follow-up (median 33 years [IQR 24-37]), 636 (13%) developed type 2 diabetes. Elevated 1-h glucose was associated with incident diabetes (hazard ratio 3.40 [95% CI 2.90-3.98], < 0.001) and provided better risk assessment than impaired glucose tolerance (Harrell concordance index 0.637 vs. 0.511, < 0.001). Addition of a 1-h measurement in subjects stratified by fasting glucose provided greater net reclassification improvement than the addition of a 2-h measurement (0.214 vs. 0.016, respectively). Finally, the 1-h glucose was significantly associated with vascular complications and mortality. The 1-h blood glucose level is a stronger predictor of future type 2 diabetes than the 2-h level and is associated with diabetes complications and mortality.
OBJECTIVE To examine whether the 1-h blood glucose measurement would be a more suitable screening tool for assessing the risk of diabetes and its complications than the 2-h measurement. RESEARCH DESIGN AND METHODS We conducted a prospective population-based cohort study of 4,867men, randomly selected fromprespecified birth cohorts between 1921 and 1949,who underwent an oral glucose tolerance test with blood glucose measurements at 0, 1, and 2 h. Subjects were followed for up to 39 years, with registry-based recording of events. Discriminative abilities of elevated 1-h (≥8.6 mmol/L) versus 2-h (≥7.8 mmol/L) glucose for predicting incident type 2 diabetes, vascular complications, andmortality were compared using Kaplan-Meier analysis, Cox proportional hazards regression, and net reclassification improvement. RESULTS Median agewas 48 years (interquartile range [IQR] 48-49). During follow-up (median 33 years [IQR 24-37]), 636 (13%) developed type 2 diabetes. Elevated 1-h glucose was associatedwith incident diabetes (hazard ratio 3.40 [95% CI 2.90-3.98], P < 0.001) and provided better risk assessment than impaired glucose tolerance (Harrell concordance index 0.637 vs. 0.511, P < 0.001). Addition of a 1-hmeasurement in subjects stratified by fasting glucose provided greater net reclassification improvement than the addition of a 2-h measurement (0.214 vs. 0.016, respectively). Finally, the 1-h glucose was significantly associated with vascular complications and mortality. CONCLUSIONS The 1-h blood glucose level is a stronger predictor of future type 2 diabetes than the 2-h level and is associated with diabetes complications and mortality.
OBJECTIVE To examine whether the 1-h blood glucose measurement would be a more suitable screening tool for assessing the risk of diabetes and its complications than the 2-h measurement. RESEARCH DESIGN AND METHODS We conducted a prospective population-based cohort study of 4,867 men, randomly selected from prespecified birth cohorts between 1921 and 1949, who underwent an oral glucose tolerance test with blood glucose measurements at 0, 1, and 2 h. Subjects were followed for up to 39 years, with registry-based recording of events. Discriminative abilities of elevated 1-h (=8.6 mmol/L) versus 2-h (=7.8 mmol/L) glucose for predicting incident type 2 diabetes, vascular complications, and mortality were compared using Kaplan-Meier analysis, Cox proportional hazards regression, and net reclassification improvement. RESULTS Median age was 48 years (interquartile range [IQR] 48-49). During follow-up (median 33 years [IQR 24-37]), 636 (13%) developed type 2 diabetes. Elevated 1-h glucose was associated with incident diabetes (hazard ratio 3.40 [95% CI 2.90-3.98], P < 0.001) and provided better risk assessment than impaired glucose tolerance (Harrell concordance index 0.637 vs. 0.511, P < 0.001). Addition of a 1-h measurement in subjects stratified by fasting glucose provided greater net reclassification improvement than the addition of a 2-h measurement (0.214 vs. 0.016, respectively). Finally, the 1-h glucose was significantly associated with vascular complications and mortality. CONCLUSIONS The 1-h blood glucose level is a stronger predictor of future type 2 diabetes than the 2-h level and is associated with diabetes complications and mortality.
Author Pareek, Manan
Eriksson, Karl-Fredrik
Bergman, Michael
Nielsen, Mette L.
Nilsson, Peter M.
Bhatt, Deepak L.
Jagannathan, Ram
Olsen, Michael H.
Author_xml – sequence: 1
  givenname: Manan
  orcidid: 0000-0002-0867-5825
  surname: Pareek
  fullname: Pareek, Manan
  organization: Brigham and Women’s Hospital Heart & Vascular Center, Harvard Medical School, Boston, MA, Cardiovascular and Metabolic Preventive Clinic, Department of Endocrinology, Centre for Individualized Medicine in Arterial Diseases, Odense University Hospital, Odense, Denmark, Cardiology Section, Department of Internal Medicine, Holbaek Hospital, Holbaek, Denmark
– sequence: 2
  givenname: Deepak L.
  surname: Bhatt
  fullname: Bhatt, Deepak L.
  organization: Brigham and Women’s Hospital Heart & Vascular Center, Harvard Medical School, Boston, MA
– sequence: 3
  givenname: Mette L.
  surname: Nielsen
  fullname: Nielsen, Mette L.
  organization: Cardiovascular and Metabolic Preventive Clinic, Department of Endocrinology, Centre for Individualized Medicine in Arterial Diseases, Odense University Hospital, Odense, Denmark
– sequence: 4
  givenname: Ram
  surname: Jagannathan
  fullname: Jagannathan, Ram
  organization: Center for Healthful Behavior Change, Department of Population Health, New York University School of Medicine, New York, NY
– sequence: 5
  givenname: Karl-Fredrik
  surname: Eriksson
  fullname: Eriksson, Karl-Fredrik
  organization: Department of Clinical Sciences and Lund University Diabetes Centre, Lund University, Skåne University Hospital, Malmö, Sweden
– sequence: 6
  givenname: Peter M.
  surname: Nilsson
  fullname: Nilsson, Peter M.
  organization: Department of Clinical Sciences and Lund University Diabetes Centre, Lund University, Skåne University Hospital, Malmö, Sweden
– sequence: 7
  givenname: Michael
  surname: Bergman
  fullname: Bergman, Michael
  organization: Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, and Diabetes Prevention Program, New York University Langone Health, New York University School of Medicine, New York, NY
– sequence: 8
  givenname: Michael H.
  surname: Olsen
  fullname: Olsen, Michael H.
  organization: Cardiovascular and Metabolic Preventive Clinic, Department of Endocrinology, Centre for Individualized Medicine in Arterial Diseases, Odense University Hospital, Odense, Denmark, Cardiology Section, Department of Internal Medicine, Holbaek Hospital, Holbaek, Denmark
BackLink https://www.ncbi.nlm.nih.gov/pubmed/29138275$$D View this record in MEDLINE/PubMed
https://lup.lub.lu.se/record/c425b721-e539-4e88-8475-dd9c4af51632$$DView record from Swedish Publication Index
oai:portal.research.lu.se:publications/c425b721-e539-4e88-8475-dd9c4af51632$$DView record from Swedish Publication Index
BookMark eNqNksFrFDEUxoNU7LZ68B-QgBc9jE0mySTxVpfaCgstuJ5DJvOGTclOxmSmsv-92e7WQ0XwEHL5ve99fO87QydDHACht5R8qhmTF52jsqJM0BdoQTUTlRBcnaAFoVxXQuv6FJ3lfE8I4VypV-i01pSpWooFylfDxg4OOnyXoPNu8g-Al3a0rQ9-2uHYY4tpdRPnhG-TDfg6zC5mwOsYIO0n8Rry9BlfFoGYRzgo3MVxDnbycai-2FzUl3ET04S_T3O3e41e9jZkeHP8z9GPr1fr5U21ur3-trxcVU4wNVUdp9BKLhVVUnbaOa2BOdvXLZOEqEbUTnStAk1aanXvNCeNLlG4FppeK8fOkT3o5l8wzq0Zk9_atDPRejMWNzaYBBlschsTZpPBFCp49-g7G8dr0cqaGhBMGw5KGcWlMF3xwm0vaMPqsmP1zx1hHstrj9r_KffhIDem-HMuwZqtzw5CsAPEORuqGy5JXe5Y0PfP0PtypKEEWihNFG1E0xTq3ZGa2y10f_w9NaAAFwfAlfPlBL1xfnpMYErWB0OJ2XfM7Dtm9h0rEx-fTTyJ_s3-Bm050Ik
CitedBy_id crossref_primary_10_1177_11795514231177206
crossref_primary_10_4158_EP_2019_0387
crossref_primary_10_3390_biomedicines12020363
crossref_primary_10_1111_jdi_14308
crossref_primary_10_1007_s15006_018_0328_0
crossref_primary_10_2337_dc19_1975
crossref_primary_10_3389_fgwh_2024_1391213
crossref_primary_10_1155_2022_4875993
crossref_primary_10_3390_nu17010152
crossref_primary_10_1016_j_diabres_2021_108650
crossref_primary_10_1111_pedi_12803
crossref_primary_10_1016_j_diabres_2024_111941
crossref_primary_10_1186_s12967_019_1787_5
crossref_primary_10_1016_j_ctim_2019_102280
crossref_primary_10_1016_j_amepre_2019_07_021
crossref_primary_10_1111_jdi_13213
crossref_primary_10_1186_s12902_018_0286_7
crossref_primary_10_3389_fendo_2023_1260623
crossref_primary_10_1210_jc_2018_02166
crossref_primary_10_2337_db24_0652
crossref_primary_10_1152_physrev_00015_2022
crossref_primary_10_3390_genes13122277
crossref_primary_10_1007_s11695_021_05259_3
crossref_primary_10_1371_journal_pone_0246568
crossref_primary_10_1016_j_diabres_2021_108883
crossref_primary_10_1016_j_diabres_2024_111856
crossref_primary_10_1016_j_heliyon_2025_e42880
crossref_primary_10_1016_j_diabres_2024_111973
crossref_primary_10_1016_j_numecd_2021_10_016
crossref_primary_10_1111_jdi_13245
crossref_primary_10_30682_ildia1901a
crossref_primary_10_1016_j_jcf_2019_07_006
crossref_primary_10_1007_s40618_023_02111_6
crossref_primary_10_3390_biomedicines11123242
crossref_primary_10_1136_bmjdrc_2019_000837
crossref_primary_10_1111_pedi_12700
crossref_primary_10_1016_j_diabres_2022_109980
crossref_primary_10_2337_dc17_2530
crossref_primary_10_1210_clinem_dgac017
crossref_primary_10_3389_fendo_2022_871965
crossref_primary_10_1016_j_dsx_2022_102630
crossref_primary_10_1016_j_diabres_2024_111963
crossref_primary_10_2337_dc20_1688
crossref_primary_10_2147_JMDH_S493128
crossref_primary_10_1507_endocrj_EJ23_0227
crossref_primary_10_1016_j_diabres_2021_109156
crossref_primary_10_2337_dc22_1894
crossref_primary_10_1038_s41440_021_00749_4
crossref_primary_10_1016_j_diabet_2022_101395
crossref_primary_10_2337_dc18_0279
crossref_primary_10_31083_j_ceog4910219
crossref_primary_10_7197_cmj_1170079
crossref_primary_10_1210_clinem_dgae748
crossref_primary_10_1080_07853890_2021_1902557
crossref_primary_10_1016_j_diabres_2025_112056
crossref_primary_10_3389_fcvm_2022_947292
crossref_primary_10_1007_s12020_022_03109_5
crossref_primary_10_14341_DM12656
crossref_primary_10_1017_S0007114521004153
crossref_primary_10_1016_j_mmm_2020_06_022
crossref_primary_10_1038_s41387_019_0084_y
crossref_primary_10_2337_dc17_2714
crossref_primary_10_1016_j_diabres_2020_108075
crossref_primary_10_2337_dc17_1900
crossref_primary_10_1111_dme_14330
crossref_primary_10_1016_j_diabres_2020_108233
crossref_primary_10_1210_jc_2018_01828
crossref_primary_10_1159_000515730
crossref_primary_10_1515_jpem_2021_0745
crossref_primary_10_3390_jcm13175200
crossref_primary_10_1016_j_diabres_2024_111589
crossref_primary_10_1177_1479164119896978
crossref_primary_10_1093_eurheartj_ehad192
crossref_primary_10_1007_s42000_022_00359_w
crossref_primary_10_1210_jc_2018_00468
crossref_primary_10_1002_dmrr_3096
crossref_primary_10_1136_bmjdrc_2019_001156
crossref_primary_10_3390_ijerph20115961
crossref_primary_10_3390_ijerph20010787
crossref_primary_10_1016_j_diabres_2023_110839
crossref_primary_10_1016_j_dsx_2019_06_029
crossref_primary_10_1016_j_diabres_2021_108683
crossref_primary_10_1186_s13098_023_01039_4
crossref_primary_10_1007_s00125_018_4798_5
crossref_primary_10_1016_S2213_8587_18_30234_1
crossref_primary_10_3390_jcm11144124
crossref_primary_10_1016_j_metabol_2024_155910
crossref_primary_10_1186_s12933_022_01590_w
crossref_primary_10_1016_j_diabres_2025_112075
crossref_primary_10_1055_a_1516_3850
crossref_primary_10_1007_s00592_022_01963_3
crossref_primary_10_1111_dom_13640
crossref_primary_10_1002_dmrr_2992
crossref_primary_10_1007_s00592_018_1105_3
crossref_primary_10_1016_j_diabres_2018_09_017
crossref_primary_10_1016_j_lanwpc_2024_101278
crossref_primary_10_1016_j_diabres_2021_109004
crossref_primary_10_1210_jendso_bvac055
crossref_primary_10_1016_j_metop_2022_100200
crossref_primary_10_1038_s41598_021_87266_z
crossref_primary_10_1016_j_numecd_2020_06_020
crossref_primary_10_1016_j_jdiacomp_2023_108551
crossref_primary_10_1210_clinem_dgae632
crossref_primary_10_3390_molecules26051393
crossref_primary_10_1016_j_diabres_2020_108009
Cites_doi 10.1056/NEJMcp1103643
10.1016/S0895-4356(97)00201-1
10.1016/j.atherosclerosis.2009.04.006
10.1016/S0140-6736(02)08905-5
10.1089/dia.2013.0025
10.2337/dc11-2181
10.1001/archinternmed.2011.183
10.1530/EJE-15-1221
10.1046/j.1365-2796.2000.00568.x
10.1016/j.annepidem.2005.10.008
10.2337/diab.27.1.42
10.2337/diab.28.12.1039
10.1371/journal.pone.0044470
10.1007/BF00400196
10.1056/NEJM200105033441801
10.2337/diab.19.11.852
10.2337/dc12-2625
10.1001/jama.1982.03320430047030
10.1007/s00125-014-3390-x
10.1161/CIRCULATIONAHA.114.014796
10.2337/dc06-1331
10.1210/jc.2012-3971
10.1002/dmrr.728
10.2337/dc08-1264
10.2337/diacare.2.2.105
10.1016/0006-2944(70)90093-1
10.1007/BF00404139
10.2337/dc10-0433
10.1136/bmj.i6538
10.1210/jc.2015-2573
10.1002/sim.4085
10.1056/NEJMoa012512
10.1001/archinternmed.2011.275
10.1046/j.1464-5491.2002.00835.x
10.1007/s001250051024
10.2337/dc08-0225
10.2337/dc11-0155
10.2337/dc10-1581
10.1016/j.diabres.2016.08.013
ContentType Journal Article
Copyright 2017 by the American Diabetes Association.
Copyright American Diabetes Association Jan 1, 2018
Copyright_xml – notice: 2017 by the American Diabetes Association.
– notice: Copyright American Diabetes Association Jan 1, 2018
CorporateAuthor Lunds universitet
Profile areas and other strong research environments
Translational Muscle Research
Department of Clinical Sciences, Malmö
Lund University
Translationell muskelforskning
Strategiska forskningsområden (SFO)
EpiHealth: Epidemiology for Health
Faculty of Medicine
Internmedicin - epidemiologi
Strategic research areas (SRA)
Medicinska fakulteten
Profilområden och andra starka forskningsmiljöer
Institutionen för kliniska vetenskaper, Malmö
Internal Medicine - Epidemiology
CorporateAuthor_xml – name: Faculty of Medicine
– name: Medicinska fakulteten
– name: Strategiska forskningsområden (SFO)
– name: Translationell muskelforskning
– name: EpiHealth: Epidemiology for Health
– name: Institutionen för kliniska vetenskaper, Malmö
– name: Internal Medicine - Epidemiology
– name: Strategic research areas (SRA)
– name: Lunds universitet
– name: Translational Muscle Research
– name: Profilområden och andra starka forskningsmiljöer
– name: Lund University
– name: Profile areas and other strong research environments
– name: Internmedicin - epidemiologi
– name: Department of Clinical Sciences, Malmö
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
K9.
NAPCQ
7X8
ADTPV
AOWAS
D95
DOI 10.2337/dc17-1351
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
MEDLINE - Academic
SwePub
SwePub Articles
SWEPUB Lunds universitet
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE

ProQuest Health & Medical Complete (Alumni)

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1935-5548
EndPage 177
ExternalDocumentID oai_portal_research_lu_se_publications_c425b721_e539_4e88_8475_dd9c4af51632
oai_lup_lub_lu_se_c425b721_e539_4e88_8475_dd9c4af51632
29138275
10_2337_dc17_1351
Genre Journal Article
GroupedDBID ---
-ET
..I
.XZ
08P
0R~
18M
29F
2WC
4.4
53G
5GY
5RE
5RS
5VS
6PF
8R4
8R5
AAFWJ
AAIKC
AAMNW
AAWTL
AAYEP
AAYXX
ABOCM
ABPPZ
ACGFO
ACGOD
ADBBV
AEGXH
AENEX
AERZD
AFOSN
AFRAH
AHMBA
AIAGR
ALIPV
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BENPR
BTFSW
CITATION
CS3
DIK
DU5
E3Z
EBS
EDB
EJD
EMOBN
EX3
F5P
GX1
H13
HZ~
IAO
IEA
IHR
INH
INR
IOF
IPO
KQ8
L7B
M0K
M5~
O5R
O5S
O9-
OK1
OVD
P2P
PCD
Q2X
RHI
SV3
TDI
TEORI
TR2
TWZ
VVN
W8F
WH7
WOQ
WOW
YHG
YOC
~KM
.55
.GJ
3O-
41~
7RV
7X2
7X7
88E
88I
8AF
8AO
8C1
8F7
8FE
8FH
8FI
8FJ
8G5
AAKAS
AAQOH
AAQQT
AAYJJ
ABUWG
ADZCM
AFFNX
AFKRA
AI.
AN0
AQUVI
ATCPS
AZQEC
BCR
BCU
BEC
BHPHI
BKEYQ
BKNYI
BLC
BNQBC
BPHCQ
BVXVI
C1A
CCPQU
CGR
CUY
CVF
DWQXO
ECM
EIF
FYUFA
GNUQQ
GUQSH
HCIFZ
HMCUK
IAG
ITC
J5H
K9-
M0R
M0T
M1P
M2O
M2P
M2Q
N4W
NAPCQ
NPM
PEA
PHGZT
PQQKQ
PROAC
PSQYO
S0X
SJFOW
UKHRP
VH1
WHG
X7M
ZCG
ZGI
ZXP
K9.
7X8
ADTPV
AOWAS
D95
PHGZM
PJZUB
PPXIY
ID FETCH-LOGICAL-c538t-d41eb74781877d9cc99e3caf2b37008652c5db8e90b1a9fc94069dc1cbe6f98c3
ISSN 0149-5992
1935-5548
IngestDate Thu Aug 21 06:43:58 EDT 2025
Thu Jul 03 05:23:46 EDT 2025
Fri Jul 11 02:47:53 EDT 2025
Mon Jun 30 16:46:13 EDT 2025
Thu Apr 03 07:05:02 EDT 2025
Thu Apr 24 23:12:33 EDT 2025
Tue Jul 01 04:11:53 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License 2017 by the American Diabetes Association.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c538t-d41eb74781877d9cc99e3caf2b37008652c5db8e90b1a9fc94069dc1cbe6f98c3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-0867-5825
PMID 29138275
PQID 1990816566
PQPubID 47715
PageCount 7
ParticipantIDs swepub_primary_oai_portal_research_lu_se_publications_c425b721_e539_4e88_8475_dd9c4af51632
swepub_primary_oai_lup_lub_lu_se_c425b721_e539_4e88_8475_dd9c4af51632
proquest_miscellaneous_1964702044
proquest_journals_1990816566
pubmed_primary_29138275
crossref_citationtrail_10_2337_dc17_1351
crossref_primary_10_2337_dc17_1351
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2018-01-01
PublicationDateYYYYMMDD 2018-01-01
PublicationDate_xml – month: 01
  year: 2018
  text: 2018-01-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Alexandria
PublicationTitle Diabetes care
PublicationTitleAlternate Diabetes Care
PublicationYear 2018
Publisher American Diabetes Association
Publisher_xml – name: American Diabetes Association
References Sayetta (2022031301255071500_B45) 1979; 2
2022031301255071500_B41
Berglund (2022031301255071500_B23) 2000; 247
Tuomilehto (2022031301255071500_B3) 2001; 344
Eriksson (2022031301255071500_B22) 1998; 41
Unwin (2022031301255071500_B9) 2002; 19
2022031301255071500_B24
Chiasson (2022031301255071500_B5) 2002; 359
Fiorentino (2022031301255071500_B15) 2015; 100
Abdul-Ghani (2022031301255071500_B12) 2008; 31
Orencia (2022031301255071500_B32) 1997; 50
Bianchi (2022031301255071500_B20) 2013; 98
Strandberg (2022031301255071500_B34) 2011; 171
Cavender (2022031301255071500_B2) 2015; 132
American Diabetes Association (2022031301255071500_B8) 2016; 39
Alyass (2022031301255071500_B16) 2015; 58
Bergman (2022031301255071500_B18) 2016; 120
Sciacqua (2022031301255071500_B31) 2012; 7
2022031301255071500_B38
Meisinger (2022031301255071500_B33) 2006; 16
de Nobel (2022031301255071500_B42) 1978; 27
Saito (2022031301255071500_B6) 2011; 171
Succurro (2022031301255071500_B29) 2009; 207
Eriksson (2022031301255071500_B21) 1991; 34
Sciacqua (2022031301255071500_B30) 2011; 34
Pencina (2022031301255071500_B28) 2011; 30
Balkau (2022031301255071500_B39) 2011; 34
Eriksson (2022031301255071500_B25) 1990; 33
2022031301255071500_B35
Sisk (2022031301255071500_B40) 1970; 19
Abdul-Ghani (2022031301255071500_B10) 2007; 30
National Diabetes Data Group (2022031301255071500_B43) 1979; 28
Abdul-Ghani (2022031301255071500_B13) 2009; 32
Nielsen (2022031301255071500_B17) 2016; 174
Dankner (2022031301255071500_B11) 2007; 23
American Diabetes Association (2022031301255071500_B1) 2013; 36
Inzucchi (2022031301255071500_B7) 2012; 367
Priya (2022031301255071500_B14) 2013; 15
Knowler (2022031301255071500_B4) 2002; 346
Marini (2022031301255071500_B19) 2012; 35
Barry (2022031301255071500_B37) 2017; 356
2022031301255071500_B26
Harrell (2022031301255071500_B27) 1982; 247
Carroll (2022031301255071500_B44) 1970; 4
Olson (2022031301255071500_B36) 2010; 33
29582286 - MMW Fortschr Med. 2018 Mar;160(Suppl 1):29
29678871 - Diabetes Care. 2018 May;41(5):e81
References_xml – volume: 367
  start-page: 542
  year: 2012
  ident: 2022031301255071500_B7
  article-title: Clinical practice. Diagnosis of diabetes
  publication-title: N Engl J Med
  doi: 10.1056/NEJMcp1103643
– volume: 50
  start-page: 1369
  year: 1997
  ident: 2022031301255071500_B32
  article-title: One-hour postload plasma glucose and risks of fatal coronary heart disease and stroke among nondiabetic men and women: the Chicago Heart Association Detection Project in Industry (CHA) Study
  publication-title: J Clin Epidemiol
  doi: 10.1016/S0895-4356(97)00201-1
– ident: 2022031301255071500_B35
– volume: 207
  start-page: 245
  year: 2009
  ident: 2022031301255071500_B29
  article-title: Elevated one-hour post-load plasma glucose levels identifies subjects with normal glucose tolerance but early carotid atherosclerosis
  publication-title: Atherosclerosis
  doi: 10.1016/j.atherosclerosis.2009.04.006
– volume: 359
  start-page: 2072
  year: 2002
  ident: 2022031301255071500_B5
  article-title: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(02)08905-5
– volume: 15
  start-page: 497
  year: 2013
  ident: 2022031301255071500_B14
  article-title: 1-hour venous plasma glucose and incident prediabetes and diabetes in Asian indians
  publication-title: Diabetes Technol Ther
  doi: 10.1089/dia.2013.0025
– volume: 35
  start-page: 868
  year: 2012
  ident: 2022031301255071500_B19
  article-title: Insulin sensitivity, β-cell function, and incretin effect in individuals with elevated 1-hour postload plasma glucose levels
  publication-title: Diabetes Care
  doi: 10.2337/dc11-2181
– volume: 171
  start-page: 941
  year: 2011
  ident: 2022031301255071500_B34
  article-title: One-hour glucose, mortality, and risk of diabetes: a 44-year prospective study in men
  publication-title: Arch Intern Med
  doi: 10.1001/archinternmed.2011.183
– volume: 174
  start-page: 591
  year: 2016
  ident: 2022031301255071500_B17
  article-title: Follow-up duration influences the relative importance of OGTT and optimal timing of glucose measurements for predicting future type 2 diabetes
  publication-title: Eur J Endocrinol
  doi: 10.1530/EJE-15-1221
– volume: 247
  start-page: 19
  year: 2000
  ident: 2022031301255071500_B23
  article-title: Long-term outcome of the Malmö Preventive Project: mortality and cardiovascular morbidity
  publication-title: J Intern Med
  doi: 10.1046/j.1365-2796.2000.00568.x
– volume: 16
  start-page: 534
  year: 2006
  ident: 2022031301255071500_B33
  article-title: Postload plasma glucose and 30-year mortality among nondiabetic middle-aged men from the general population: the ERFORT Study
  publication-title: Ann Epidemiol
  doi: 10.1016/j.annepidem.2005.10.008
– volume: 27
  start-page: 42
  year: 1978
  ident: 2022031301255071500_B42
  article-title: The size of the loading dose as an important determinant of the results of the oral glucose tolerance test: a study in subjects with slightly impaired glucose tolerance
  publication-title: Diabetes
  doi: 10.2337/diab.27.1.42
– volume: 28
  start-page: 1039
  year: 1979
  ident: 2022031301255071500_B43
  article-title: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance
  publication-title: Diabetes
  doi: 10.2337/diab.28.12.1039
– volume: 7
  start-page: e44470
  year: 2012
  ident: 2022031301255071500_B31
  article-title: Association between one-hour post-load plasma glucose levels and vascular stiffness in essential hypertension
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0044470
– volume: 34
  start-page: 891
  year: 1991
  ident: 2022031301255071500_B21
  article-title: Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmö Feasibility Study
  publication-title: Diabetologia
  doi: 10.1007/BF00400196
– volume: 344
  start-page: 1343
  year: 2001
  ident: 2022031301255071500_B3
  article-title: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance
  publication-title: N Engl J Med
  doi: 10.1056/NEJM200105033441801
– volume: 19
  start-page: 852
  year: 1970
  ident: 2022031301255071500_B40
  article-title: Comparison of the 50 and 100 gram oral glucose tolerance test
  publication-title: Diabetes
  doi: 10.2337/diab.19.11.852
– volume: 36
  start-page: 1033
  year: 2013
  ident: 2022031301255071500_B1
  article-title: Economic costs of diabetes in the U.S. in 2012
  publication-title: Diabetes Care
  doi: 10.2337/dc12-2625
– volume: 247
  start-page: 2543
  year: 1982
  ident: 2022031301255071500_B27
  article-title: Evaluating the yield of medical tests
  publication-title: JAMA
  doi: 10.1001/jama.1982.03320430047030
– volume: 58
  start-page: 87
  year: 2015
  ident: 2022031301255071500_B16
  article-title: Modelling of OGTT curve identifies 1 h plasma glucose level as a strong predictor of incident type 2 diabetes: results from two prospective cohorts
  publication-title: Diabetologia
  doi: 10.1007/s00125-014-3390-x
– volume: 132
  start-page: 923
  year: 2015
  ident: 2022031301255071500_B2
  article-title: Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the Reduction of Atherothrombosis for Continued Health (REACH) registry
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.114.014796
– volume: 30
  start-page: 1544
  year: 2007
  ident: 2022031301255071500_B10
  article-title: What is the best predictor of future type 2 diabetes
  publication-title: Diabetes Care
  doi: 10.2337/dc06-1331
– volume: 98
  start-page: 2100
  year: 2013
  ident: 2022031301255071500_B20
  article-title: Elevated 1-hour postload plasma glucose levels identify subjects with normal glucose tolerance but impaired β-cell function, insulin resistance, and worse cardiovascular risk profile: the GENFIEV study
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jc.2012-3971
– ident: 2022031301255071500_B38
– volume: 39
  start-page: S1
  year: 2016
  ident: 2022031301255071500_B8
  article-title: Standards of Medical Care in Diabetes—2016
  publication-title: Diabetes Care
– volume: 23
  start-page: 551
  year: 2007
  ident: 2022031301255071500_B11
  article-title: Predicting the 20-year diabetes incidence rate
  publication-title: Diabetes Metab Res Rev
  doi: 10.1002/dmrr.728
– volume: 32
  start-page: 281
  year: 2009
  ident: 2022031301255071500_B13
  article-title: Fasting versus postload plasma glucose concentration and the risk for future type 2 diabetes: results from the Botnia Study
  publication-title: Diabetes Care
  doi: 10.2337/dc08-1264
– volume: 2
  start-page: 105
  year: 1979
  ident: 2022031301255071500_B45
  article-title: Summary of current diabetes-related data from the National Center for Health Statistics
  publication-title: Diabetes Care
  doi: 10.2337/diacare.2.2.105
– volume: 4
  start-page: 171
  year: 1970
  ident: 2022031301255071500_B44
  article-title: A colorimetric serum glucose determination using hexokinase and glucose-6-phosphate dehydrogenase
  publication-title: Biochem Med
  doi: 10.1016/0006-2944(70)90093-1
– volume: 33
  start-page: 526
  year: 1990
  ident: 2022031301255071500_B25
  article-title: Impaired glucose tolerance in a middle-aged male urban population: a new approach for identifying high-risk cases
  publication-title: Diabetologia
  doi: 10.1007/BF00404139
– volume: 33
  start-page: 2184
  year: 2010
  ident: 2022031301255071500_B36
  article-title: Screening for diabetes and pre-diabetes with proposed A1C-based diagnostic criteria
  publication-title: Diabetes Care
  doi: 10.2337/dc10-0433
– volume: 356
  start-page: i6538
  year: 2017
  ident: 2022031301255071500_B37
  article-title: Efficacy and effectiveness of screen and treat policies in prevention of type 2 diabetes: systematic review and meta-analysis of screening tests and interventions
  publication-title: BMJ
  doi: 10.1136/bmj.i6538
– volume: 100
  start-page: 3744
  year: 2015
  ident: 2022031301255071500_B15
  article-title: One-hour postload hyperglycemia is a stronger predictor of type 2 diabetes than impaired fasting glucose
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jc.2015-2573
– volume: 30
  start-page: 11
  year: 2011
  ident: 2022031301255071500_B28
  article-title: Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers
  publication-title: Stat Med
  doi: 10.1002/sim.4085
– volume: 346
  start-page: 393
  year: 2002
  ident: 2022031301255071500_B4
  article-title: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa012512
– ident: 2022031301255071500_B24
– ident: 2022031301255071500_B26
– volume: 171
  start-page: 1352
  year: 2011
  ident: 2022031301255071500_B6
  article-title: Lifestyle modification and prevention of type 2 diabetes in overweight Japanese with impaired fasting glucose levels: a randomized controlled trial
  publication-title: Arch Intern Med
  doi: 10.1001/archinternmed.2011.275
– volume: 19
  start-page: 708
  year: 2002
  ident: 2022031301255071500_B9
  article-title: Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention
  publication-title: Diabet Med
  doi: 10.1046/j.1464-5491.2002.00835.x
– volume: 41
  start-page: 1010
  year: 1998
  ident: 2022031301255071500_B22
  article-title: No excess 12-year mortality in men with impaired glucose tolerance who participated in the Malmö Preventive Trial with diet and exercise
  publication-title: Diabetologia
  doi: 10.1007/s001250051024
– volume: 31
  start-page: 1650
  year: 2008
  ident: 2022031301255071500_B12
  article-title: One-hour plasma glucose concentration and the metabolic syndrome identify subjects at high risk for future type 2 diabetes
  publication-title: Diabetes Care
  doi: 10.2337/dc08-0225
– volume: 34
  start-page: 1406
  year: 2011
  ident: 2022031301255071500_B30
  article-title: One-hour postload plasma glucose levels and left ventricular mass in hypertensive patients
  publication-title: Diabetes Care
  doi: 10.2337/dc11-0155
– volume: 34
  start-page: 957
  year: 2011
  ident: 2022031301255071500_B39
  article-title: Are the same clinical risk factors relevant for incident diabetes defined by treatment, fasting plasma glucose, and HbA1c
  publication-title: Diabetes Care
  doi: 10.2337/dc10-1581
– volume: 120
  start-page: 221
  year: 2016
  ident: 2022031301255071500_B18
  article-title: One-hour post-load plasma glucose level during the OGTT predicts dysglycemia: observations from the 24year follow-up of the Israel Study of Glucose Intolerance, Obesity and Hypertension
  publication-title: Diabetes Res Clin Pract
  doi: 10.1016/j.diabres.2016.08.013
– ident: 2022031301255071500_B41
– reference: 29678871 - Diabetes Care. 2018 May;41(5):e81
– reference: 29582286 - MMW Fortschr Med. 2018 Mar;160(Suppl 1):29
SSID ssj0004488
Score 2.5548174
Snippet To examine whether the 1-h blood glucose measurement would be a more suitable screening tool for assessing the risk of diabetes and its complications than the...
OBJECTIVE To examine whether the 1-h blood glucose measurement would be a more suitable screening tool for assessing the risk of diabetes and its complications...
SourceID swepub
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 171
SubjectTerms Adult
Blood
Blood Glucose - metabolism
Body Mass Index
Clinical Medicine
Cohort analysis
Complications
Diabetes
Diabetes Complications - blood
Diabetes Complications - diagnosis
Diabetes Complications - epidemiology
Diabetes mellitus
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Type 2 - blood
Diabetes Mellitus, Type 2 - diagnosis
Diabetes Mellitus, Type 2 - epidemiology
Diagnostic tests
Endocrinology and Diabetes
Endokrinologi och diabetes
Female
Follow-Up Studies
Glucose
Glucose Intolerance - blood
Glucose Intolerance - diagnosis
Glucose tolerance
Glucose Tolerance Test
Hazards
Health risk assessment
Health risks
Humans
Kaplan-Meier Estimate
Klinisk medicin
Male
Medical and Health Sciences
Medicin och hälsovetenskap
Middle Aged
Mortality
Population studies
Population-based studies
Prevalence
Prospective Studies
Quantitative analysis
Reclassification
Regression analysis
Research design
Risk Assessment
Time Factors
Title Enhanced Predictive Capability of a 1-Hour Oral Glucose Tolerance Test: A Prospective Population-Based Cohort Study
URI https://www.ncbi.nlm.nih.gov/pubmed/29138275
https://www.proquest.com/docview/1990816566
https://www.proquest.com/docview/1964702044
https://lup.lub.lu.se/record/c425b721-e539-4e88-8475-dd9c4af51632
oai:portal.research.lu.se:publications/c425b721-e539-4e88-8475-dd9c4af51632
Volume 41
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Jj9MwFLZgkBAXxE5hQAZxQKoCTWI3NrdZCtWgGYrUkUZcLNtxKJpOWnU5wK_nvThbS5EGDomq2LUjvy9vsd9CyJs0YqIvdRZoG_KAJWkWSB2aIMuM6Dnr0l6RYuP0rD88ZycX_KJ1YorRJSvzzv7aGVfyP1SFZ0BXjJL9B8rWg8ID-A30hTtQGO7XovEgn_gD_NECz1sKL6AjkH6Fw-tPH_oYBkMYqvsFA_E_lf7p49nULYpYgTEIBR-cPlrMqqjL7qiu6hUcgpRLgWtMQE0vnA43joGPq51bdCBrTqMWzl36QKC8Ad_hRPuDqGMHIvCyW-86n_1A-ex9itHxqGk50d917nf3Cyjoq_YmRShamxTOM1YZ8wBUF9HmvD7l1QbCPBsNfVmWbfYexUWCgNSCZMXKgu0-sFbzq4LOkcS8ir4ey1Yu7arpJrkVgVmBFS8-f21llwdu5rNP4Uzv63kwY3T5z0315Q-bZCvhbKGkjO-Ru6V1QQ88VO6TGy5_QG6flv4TD8myQgxtEEMbxNBZRjX1iKGIGFoihtaIoYiYD_SAtvBCt_FCPV5ogZdH5PzjYHw0DMqyG4EF6bcKUhY6g2UVQpEkqbRWShdbnUUmTtAC5pHlqRFO9kyoZWYlBk_DWlnj-pkUNn5M9vJZ7p4Sqi2XLHVWM-AJTHCpudO9OI05kzqS_Q55W62msmVOeiyNMlVgmyINFNJAIQ065HXdde4TsezqtF-RRJXf6VKFoHAJTDIF072qm4GL4tGYzt1sjX36LME4cdYhTzwp61kq0nfIwNO2bsHU7NP1HC4Dl1o6ZUEEmiQKleOxVMwJoUD94yqFdWQ642D9RB3ybcc43tpWZYqvSTnevLV3f63Bn_319Z-TO82XuU_2Vou1ewEK9cq8LL6C37VIzRY
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Enhanced+Predictive+Capability+of+a+1-Hour+Oral+Glucose+Tolerance+Test%3A+A+Prospective+Population-Based+Cohort+Study&rft.jtitle=Diabetes+care&rft.au=Pareek%2C+Manan&rft.au=Bhatt%2C+Deepak+L&rft.au=Nielsen%2C+Mette+L&rft.au=Jagannathan%2C+Ram&rft.date=2018-01-01&rft.eissn=1935-5548&rft.volume=41&rft.issue=1&rft.spage=171&rft_id=info:doi/10.2337%2Fdc17-1351&rft_id=info%3Apmid%2F29138275&rft.externalDocID=29138275
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0149-5992&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0149-5992&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0149-5992&client=summon